Lipid lowering therapy in type 2 diabetes

Wiener Medizinische Wochenschrift

Volumn 161, Issue 11-12, 2011, Pages 289-296

  Föger, Bernhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fibrates; HDL cholesterol; LDL cholesterol; Niacin; Statins; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC DYSLIPIDEMIA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; GENE; HEART INFARCTION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS (TOPIC); MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT CARE; RHABDOMYOLYSIS; SLCO1B1 GENE; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; TRIGLYCERIDES;

EID: 80052491945     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-011-0908-4     Document Type: Article

References (60)

1. Föger B, Patsch JR. Postprandial lipemia. In: Betteridge DJ (ed) Lipids: current perspectives II. Martin Dunitz Publishers, London, 2000, pp 1-14
2. B Föger A Ritsch A Doblinger, et al. 1996 Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia Art Thromb Vasc Biol 16 1430 1436 10.1161/01.ATV.16.12.1430 (Pubitemid 26427595)
3. B Föger M Chase MJ Amar, et al. 1999 Expression of cholesteryl ester transfer protein (CETP) ameliorates early aortic atherosclerosis in lecithin:cholesterol acyltransferase (LCAT)-transgenic mice J Biol Chem 274 36912 36920 10601244 10.1074/jbc.274.52.36912 (Pubitemid 30016758)
4. American Diabetes Organisation 2010 Clinical Practice Recommendations Diabetes Care 33 S30 S32 10.2337/dc10-zb03
5. TC Wascher 2009 Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2 Wien Klin Wochenschrift 121 Suppl. 5 S25 S27
6. Österreichischer Lipidkonsensus 2010; www.aas.at
7. SM Grundy JI Cleeman CNB Merz, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317. 49796.0E (Pubitemid 38924592)
8. PJ Barter CM Ballantyne R Carmena, et al. 2006 Apo B cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Int Med 259 247 258 10.1111/j.1365-2796.2006. 01616.x 1:CAS:528:DC%2BD28XjslCmtLY%3D
9. L Weiquan HE Resnick KA Jablonski, et al. 2003 Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes Diabetes Care 26 16 23 10.2337/diacare.26.1.16 (Pubitemid 36928989)
10. R Simmons RL Coleman HC Price, et al. 2009 Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort Diabetes Care 32 708 713 19114615 10.2337/dc08-1918
11. Cholesterol Treatment Trialists (CTT) Collaborators 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 10.1016/S0140-6736(05)67394-1 (Pubitemid 41416582)
12. Cholesterol Treatment Trialists Collaborators 2008 Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125 10.1016/S0140-6736(08) 60104-X
13. JG Robinson B Smith N Maheshwari, et al. 2005 Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 1855 1862 16286171 10.1016/j.jacc.2005.05.085 1:CAS:528:DC%2BD2MXht1SrtbzF (Pubitemid 41579807)
14. PM Ridker CP Cannon D Morrow, et al. 2005 C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 20 28 15635109 10.1056/NEJMoa042378 1:CAS:528:DC%2BD2MXis12msA%3D%3D (Pubitemid 40075677)
15. RH Knopp M D'Emden JG Smilde, et al. 2006 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes Diabetes Care 29 1478 1485 16801565 10.2337/dc05-2415 1:CAS:528:DC%2BD28XnsVahtbk%3D (Pubitemid 44127567)
16. JJ Brugts T Yetgin SE Hoeks, et al. 2009 The benefit of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials BMJ 338 b2376 19567909 10.1136/bmj.b2376 1:STN:280:DC%2BD1Mvls1CltQ%3D%3D
17. ALLHAT Officers 2002 The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) JAMA 288 2998 3007 10.1001/jama.288.23.2998 (Pubitemid 35471161)
18. HM Colhoun DJ Betteridge PN Durrington, et al. 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized controlled trial Lancet 364 685 696 15325833 10.1016/S0140-6736(04)16895-5 1:CAS:528:DC%2BD2cXmvFWltrY%3D (Pubitemid 39140624)
19. PS Sever B Dahlof NR Poulter, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149 1158 12686036 10.1016/S0140-6736(03)12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D (Pubitemid 36398384)
20. Cholesterol Treatment Trialists' Collaboration 2010 Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670 1681 10.1016/S0140-6736(10)61350-5
21. P Amarenco J Bogousslavsky A Callahan, et al. 2006 High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 549 559 16899775 10.1056/NEJMoa061894 1:CAS:528:DC%2BD28XotVKgtb8%3D (Pubitemid 44202151)
22. PM Ridker E Danielson FA Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
23. SE Nissen SJ Nicholls I Sipahi, et al. 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial JAMA 295 1556 1565 16533939 10.1001/jama.295.13.jpc60002 1:CAS:528: DC%2BD28Xjt12itrc%3D
24. PH Jones MH Davidson EA Stein, et al. 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 93 152 160 10.1016/S0002-9149(03)00530-7 (Pubitemid 36835963)
25. The SEARCH Collaborative Group 2008 SLCO1B1 variants and statin-induced myopathy - a genome-wide study N Engl J Med 359 789 799 10.1056/NEJMoa0801936
26. VG Athyros AA Papageorgiou BR Mercouris, et al. 2002 Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 220 228 12201623 10.1185/030079902125000787
27. SD Wiviott CP Cannon DA Morrow, et al. 2005 Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy J Am Coll Cardiol 46 1411 1416 16226163 10.1016/j.jacc.2005.04.064 1:CAS:528:DC%2BD2MXhtFWht7zK (Pubitemid 41446174)
28. N Sattar D Preiss HM Murray, et al. 2010 Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials Lancet 375 735 742 20167359 10.1016/S0140-6736(09)61965-6 1:CAS:528:DC%2BC3cXisFart74%3D
29. Austrian Atherosclerosis Society Cholesterin Consensus 2006. www.aas.at
30. B Föger JR Patsch 2011 LDL-cholesterin in der Sekundärprä vention: Zielwerterreichung unter Lipidsenkern in Praxis und Spital in Österreich (ZIEL) Wien Klin Wochenschr 123 21 27 21165704 10.1007/s00508-010-1498-7
31. CM Ballantyne R Weiss T Moccetti, et al. 2007 Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (EXPLORER) Am J Cardiol 99 673 680 17317370 10.1016/j.amjcard.2006.10.022 1:CAS:528:DC%2BD2sXitFOksb0%3D
32. I Holme K Boman P Brudi, et al. 2010 Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial Am J Cardiol 105 1802 1808 20538134 10.1016/j.amjcard.2010.01.363 1:CAS:528:DC%2BC3cXntlaiu7k%3D
33. JL Fleg M Mete B Howard, et al. 2008 Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial J Am Coll Cardiol 52 2198 2205 19095139 10.1016/j.jacc.2008.10.031 1:CAS:528:DC%2BD1cXhsFajs7rJ
34. JJ Kastelein F Akdim ES Stroes, et al. 2008 Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 1431 1443 18376000 10.1056/NEJMoa0800742 1:CAS:528:DC%2BD1cXkt12qt7c%3D (Pubitemid 351482735)
35. AJ Taylor TC Villines EJ Stanek, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 19915217 10.1056/NEJMoa0907569 1:CAS:528:DC%2BD1MXhsFSnsLzP
36. R Huijgen EJ Abbink E Bruckert, et al. 2010 Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial Clin Ther 32 615 625 20435231 10.1016/j.clinthera.2010.04.014 1:CAS:528:DC%2BC3cXosVSnurg%3D
37. CP Cannon RP Giugliano MA Blazing, et al. 2008 Rationale and design of IMPROVE-IT: comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 826 832 19061694 10.1016/j.ahj.2008.07.023 1:CAS:528:DC%2BD1cXht12gtLvI
38. H Drexel S Aczel T Marte, et al. 2005 Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol Diabetes Care 28 101 107 15616241 10.2337/diacare.28.1.101 1:CAS:528:DC%2BD2MXhtFWms7Y%3D (Pubitemid 40095790)
39. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 17898099 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M (Pubitemid 47481452)
40. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 499 508 17284700 10.1001/jama.297.5.499 1:CAS:528:DC%2BD2sXhs1Wis7k%3D (Pubitemid 46220805)
41. O Faergeman I Holme R Fayyad, et al. 2009 Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary heart disease Am J Cardiol 104 459 463 19660594 10.1016/j.amjcard. 2009.04.008 1:CAS:528:DC%2BD1MXpsFyltrw%3D
42. EA Schwartz J Koska MP Mullin, et al. 2010 Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes Atherosclerosis 212 217 222 20557887 10.1016/j.atherosclerosis.2010.05.028 1:CAS:528:DC%2BC3cXhtFams77M
43. MA Deeg JB Buse RB Goldberg, et al. 2007 Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 30 2458 2464 17595355 10.2337/dc06-1903 1:CAS:528:DC%2BD2sXht1CltrvF (Pubitemid 47547772)
44. M Davidson PM Meyer S Haffner, et al. 2008 Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patints with type 2 diabetes mellitus Circulation 117 2123 2130 18413496 10.1161/CIRCULATIONAHA.107.746610 1:CAS:528:DC%2BD1cXks1Gjsb4%3D (Pubitemid 351572171)
45. B Föger G Tröbinger A Ritsch, et al. 1995 Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein composition, lipoprotein-modifying enzymes, and postprandial lipoprotein metabolism Atherosclerosis 117 253 261 8801871 10.1016/0021-9150(95)05580-P
46. The DAIS Study group 2001 Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 905 910 10.1016/S0140-6736(00) 04209-4 (Pubitemid 32247277)
47. SA Saha LG Kizhakepunnur A Bahekar, et al. 2007 The role of fibrates in the prevention of cardiovascular disease: a pooled meta-analysis of long-term randomized placebo-controlled trials Am Heart J 154 943 953 17967602 10.1016/j.ahj.2007.07.011 1:CAS:528:DC%2BD2sXht1agsr3N (Pubitemid 350001283)
48. MH Frick O Elo K Haapa, et al. 1987 Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia N Engl J Med 317 1237 1245 3313041 10.1056/NEJM198711123172001 1:STN:280: DyaL1c%2FjvFSjtw%3D%3D
49. HB Rubins SJ Robins D Collins, et al. 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 410 418 10438259 10.1056/ NEJM199908053410604 1:CAS:528:DyaK1MXltlyltbw%3D (Pubitemid 29362514)
50. The ACCORD Study group 2010 Effects of combination lipid therapy in type 2 diabetes N Engl J Med 362 1563 1574 10.1056/NEJMoa1001282
51. R Scott R O'Brien G Fulcher, et al. 2009 Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome Diabetes Care 32 493 498 18984774 10.2337/dc08-1543 1:CAS:528:DC%2BD1MXjvVyqt7s%3D
52. V Manninen L Tenkanen P Koskinen, et al. 1992 Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment Circulation 85 37 45 1728471 1:STN:280:DyaK38%2FpslamtQ%3D%3D
53. The ACCORD Study group and ACCORD Eye Study group 2010 Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 233 244 10.1056/NEJMoa1001288
54. JR Guyton BG Brown S Fazio, et al. 2008 Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia J Am Coll Cardiol 51 164 1572 10.1016/j.jacc.2008.03.003 (Pubitemid 351509420)
55. HE Bays C Ballantyne 2009 What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 20 467 476 19779335 10.1097/MOL.0b013e3283325083 1:CAS:528:DC%2BD1MXhsVKls7%2FL
56. BG Brown XQ Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 11757504 10.1056/NEJMoa011090 1:CAS:528:DC%2BD3MXoslyhsLs%3D (Pubitemid 33126837)
57. PL Canner CD Furberg ML Terrin, et al. 2005 Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 254 257 15642562 10.1016/j.amjcard.2004.09.013 1:CAS:528:DC%2BD2MXisF2isA%3D%3D (Pubitemid 40092094)
58. E Bruckert J Labreuche P Amarenco 2010 Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 353 361 20079494 10.1016/j.atherosclerosis. 2009.12.023 1:CAS:528:DC%2BC3cXmslGnu78%3D
59. AIM-HIGH. www.clinicaltrials.gov
60. HPS2-THRIVE. www.clinicaltrials.gov